BiTE Therapy May Impact Standard of Care in Multiple Myeloma, Expert Says

Video

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.

The standard of care in multiple myeloma may change due to the introduction of bispecific T-cell engager (BiTE) therapy, according to Ashley E. Rosko, MD. BiTE therapy can be used to treat older patients for whom other treatments may not be viable. Rosko also remarked on transplant eligibility, and the ability to design treatments based on a patient’s health and wellness.

Rosko, an associate professor in the Department of Internal Medicine at The Ohio State University, medical director of the Oncogeriatric Program at The Ohio State University Comprehensive Cancer Center – The James, and co-director of the Cancer and Aging Resiliency Clinic at The James, spoke with CancerNetwork® after moderating a discussion at an Around the Practice® program. She and her colleagues focused on how they would approach treatment in different patient populations.

Transcript:

With the fantastic advances that we have in multiple myeloma, I’m looking forward to utilizing the bispecific T cell engager [therapy], or BiTE therapy, for patients with multiple myeloma, as well as advances in CAR T-cell therapy. Increasingly, so many of these opportunities for our patients are being utilized more and more amongst older adults with cancer as well. Myeloma is a disease [most commonly found in] aging adults. Being able to deliver these advanced therapies to all patients is an important advance in the field.

When it comes to unmet needs for patients with multiple myeloma, a lot of our decision-making is framed around [the distinction between] transplant-eligible and transplant-ineligible. Importantly, there are going to be new therapies, such as CAR T-cell therapy and others, that are offered for patients.

With this focus on transplant eligibility, we will see that this will shift, and we are seeing more and more patients getting other opportunities and other cellular therapies. Importantly, I’m looking forward being able to offer patients therapies based on their individual health and fitness.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Related Content